44.60
Boston Scientific Corp stock is traded at $44.60, with a volume of 17.12M.
It is down -1.20% in the last 24 hours and down -8.14% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$45.14
Open:
$44.81
24h Volume:
17.12M
Relative Volume:
0.82
Market Cap:
$66.29B
Revenue:
$20.62B
Net Income/Loss:
$3.56B
P/E Ratio:
18.70
EPS:
2.3847
Net Cash Flow:
$3.48B
1W Performance:
+2.58%
1M Performance:
-8.14%
6M Performance:
-54.39%
1Y Performance:
-57.25%
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corp
|
44.60 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
ABT
Abbott Laboratories
|
95.63 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
324.73 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
83.06 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
|
EW
Edwards Lifesciences Corp
|
95.18 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific’s Quarterly Earnings Preview: What You Need to Know - Barchart.com
Stifel Cuts PT on Boston Scientific Corporation (BSX)- Here’s Why - Yahoo Finance
Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo! Finance Canada
Boston Scientific Corp. stock outperforms competitors despite losses on the day - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
Boston Scientific Stock (BSX) Opinions on Recent Analyst Downgrades - Quiver Quantitative
Boston Scientific adjusts growth outlook as stock struggles. Guidance cuts weigh on sentiment - AD HOC NEWS
Boston Scientific (BSX) Invests $1.5B in MiRus for Equity Stake and TAVR Acquisition Option - Insider Monkey
Boston Scientific Corp. stock underperforms Monday when compared to competitors - MarketWatch
Boston Scientific stock hits 52-week low at 43.87 USD By Investing.com - Investing.com South Africa
Boston Scientific stock hits 52-week low at 43.87 USD - Investing.com
Boston Scientific strategy focus, shares hold in S&P 500 healthcare group - AD HOC NEWS
The WATCHMAN FLX Pro from Boston Scientific Corp.left atrial appendage closure gets smoother in c - Ad-hoc-news.de
World Implantable Neurostimulation DevicesMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
WAYCROSS PARTNERS, LLC's Boston Scientific Corp(BSX) Holding History - GuruFocus
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50? - Insider Monkey
Brain Implants Market Size to Reach USD 18.39 Billion by 2035, Growing at 9.99% CAGR | SNS Insider - GlobeNewswire Inc.
Boston Scientific Corp Investor Event at the Scientific Session of the American College of Cardiology Transcript - GuruFocus
Volkswagen Plans to Cut Up to 100,000 Jobs and Close 4 German Plants, European Auto Industry Faces Historic Restructuring - TradingKey
Boston Scientific Options Spot-On: On June 25th, 67,433 Contracts Were Traded, With 779.57K Open Interest - Moomoo
Boston Scientific (NYSE:BSX) Gains Fresh Market Attention - Kalkine Media
BSX Maintained by Stifel -- Price Target Lowered to $65.00 - GuruFocus
TD Cowen Maintains a Buy Rating on Boston Scientific (BSX) - Insider Monkey
Stifel Adjusts Price Target on Boston Scientific to $65 From $75, Maintains Buy Rating - marketscreener.com
Japan, South Korea Stocks Rally; Nikkei 225 Nears Previous High, Kospi Rises Over 5%, Memory Giants SK Hynix and Kioxia Soar Over 12% - TradingKey
Boston Scientific (BSX) Registers a Bigger Fall Than the Market: Important Facts to Note - sharewise.com
Micron Q3 Data Center Revenue Grows Over Sevenfold YoY; Shares Jump Over 14% Post-Market, Memory Supply Shortage to Last Beyond 2027 - TradingKey
How a Targeted Valve Recall and Watchman Questions at Boston Scientific (BSX) Have Changed Its Investment Story - Yahoo Finance
Boston Scientific (BSX) Recalls Orca Valves Nationwide After Device Malfunction - Yahoo Finance
BSX Maintains Buy Rating by Jefferies -- Price Target Lowered to $67.00 - GuruFocus
BSX Stock | Boston Scientific Corp Q1 2025 Earnings Call Bear Attack (FjRIiYMEgO) - Mshale
Boston Scientific (BSX) Faces 52.54% Decline Amid Weak Momentum Grades - GuruFocus
IBM (IBM) Rebounds 5% on ServiceNow AI Deal — Can It Clear $267 Resistance? - TradingKey
Jefferies Adjusts Price Target on Boston Scientific to $67 From $100, Maintains Buy Rating - marketscreener.com
Analyst recommendations: Astera Labs, Boston Scientific, Cognizant Technologies, Fedex… - marketscreener.com
Boston Scientific Corp (BSX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Boston Scientific (BSX) Gains As Market Dips: What You Should Know - Yahoo Finance
Boston Scientific Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Piper Sandler Maintains Overweight Rating for Boston Scientific (BSX) - Insider Monkey
Jim Cramer on Boston Scientific: “This Whole Cohort Is Just Too Hard to Own” - Insider Monkey
Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years - Benzinga
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Boston Scientific stock hits 52-week low at 44.41 USD By Investing.com - Investing.com Australia
Boston Scientific Spinal Cord Stimulator Lawsuit for SCS Injuries - robertkinglawfirm.com
Boston Scientific stock hits 52-week low at 44.41 USD - Investing.com UK
Truist Cuts Boston Scientific (BSX) ’s Target as Doctors Change How They Use Its Heart Device - Insider Monkey
Cramer Passes On NioCorp And SoundHound — But Says One Stock Is 'Time To Buy' - Benzinga
Boston Scientific Corp Recalls Orca Sterile Single-Use Air/Water and Suction Valves - marketscreener.com
Boston Sci-Mirus pact lifts med-tech dealmaking to record $4.5B in May - BioWorld News
Boston Scientific Corp (BSX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Boston Scientific Corp (BSX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Boston Scientific Corp Stock (BSX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pegus Cheryl | Director |
May 20 '26 |
Buy |
56.49 |
1,770 |
99,987 |
1,770 |
| LUDWIG EDWARD J | Director |
May 20 '26 |
Buy |
56.68 |
3,580 |
202,914 |
25,359 |
| Habiger David C | Director |
May 20 '26 |
Buy |
55.92 |
2,250 |
125,819 |
13,878 |
| Habiger David C | Director |
May 19 '26 |
Buy |
56.95 |
2,200 |
125,279 |
11,628 |
| O'Connor Padraig Andrew | EVP, Global Operations |
May 02 '26 |
Option Exercise |
0.00 |
1,802 |
0 |
7,896 |
| Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC |
May 02 '26 |
Option Exercise |
0.00 |
2,102 |
0 |
57,894 |
| Woodworth Emily | SVP, Global Controller and CAO |
Mar 01 '26 |
Option Exercise |
0.00 |
838 |
0 |
3,231 |
| O'Connor Padraig Andrew | EVP, Global Operations |
Feb 16 '26 |
Option Exercise |
0.00 |
905 |
0 |
6,433 |
| O'Connor Padraig Andrew | EVP, Global Operations |
Feb 14 '26 |
Option Exercise |
0.00 |
1,190 |
0 |
5,977 |
| O'Connor Padraig Andrew | EVP, Global Operations |
Feb 13 '26 |
Option Exercise |
0.00 |
500 |
0 |
4,986 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):